INTELLIGENT BIO SOLUTIONS INC. 8-K

What Happened
On June 2, 2026, Intelligent Bio Solutions, Inc. (INBS) announced via Form 8‑K (Regulation FD disclosure) that it has initiated a multi‑site Method Comparison Study to support its FDA 510(k) submission for U.S. market clearance of its Intelligent Fingerprinting Drug Screening System for the opiate codeine. The company furnished the press release announcing the study as Exhibit 99.1 to the 8‑K.

Key Details

• Announcement date: June 2, 2026 (Form 8‑K, Item 7.01).
• Program: Multi‑site Method Comparison Study intended to support a 510(k) submission to the U.S. FDA.
• Product: Intelligent Fingerprinting Drug Screening System, targeted analyte: opiate — codeine.
• Disclosure type: Regulation FD press release (Exhibit 99.1 included in the filing).

Why It Matters
This study is a regulatory‑step toward potential U.S. market clearance for INBS’s fingerprint‑based drug screening for codeine. Successful completion and positive results would be necessary components of a 510(k) submission and could enable commercialization in the U.S.; investors should note this is an early regulatory milestone rather than an approval. The filing does not provide timelines, study results, or financial impacts—future updates (study completion, 510(k) submission, FDA response) will be material events to monitor.